We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+30.91%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.29B
AUM Growth
+$94.4M
Cap. Flow
-$78.5M
Cap. Flow %
-6.1%
Top 10 Hldgs %
48.93%
Holding
207
New
56
Increased
31
Reduced
35
Closed
51

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$30.6M
2
QURE icon
uniQure
QURE
+$18.4M
3
NVRO
NEVRO CORP.
NVRO
+$16.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$12.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$12M

Top Sells

Rank Stock Value
1
PTCT icon
PTC Therapeutics
PTCT
+$34.8M
2
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$21.8M
3
ESPR
Esperion Therapeutics
ESPR
+$19.5M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$19.3M
5
TARO
Taro Pharmaceutical Industries Ltd.
TARO
+$18.5M

Sector Composition

Rank Sector Weight
1 Healthcare 84.11%
2 Miscellaneous 14.93%
3 Consumer Staples 0.85%
4 Technology 0.05%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGCD
76
DELISTED
MGC Diagnostics Corporation
MGCD
$2.48M 0.19%
336,287
– –
HEWG
77
DELISTED
iShares Currency Hedged MSCI Germany ETF
HEWG
$2.43M 0.19%
+85,000
New +$2.25M
DERM
78
DELISTED
Dermira, Inc.
DERM
$2.33M 0.18%
152,000
– –
VCEL icon
79
Vericel Corp
VCEL
$2.03B
$2.18M 0.17%
589,297
-260,703
-31% -$888K
EIGR
80
PUT
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.89M 0.15%
+222
New +$1.94M
GNVC
81
DELISTED
GenVec, Inc.
GNVC
$1.81M 0.14%
61,584
-42,450
-41% -$1.39M
BCLI
82
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.78M 0.14%
+26,667
New +$1.69M
DRRX
83
DELISTED
DURECT Corp
DRRX
$1.73M 0.13%
90,706
– –
WBA
84
DELISTED
Walgreens Boots Alliance
WBA
$1.72M 0.13%
20,292
– –
VIRX
85
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.72M 0.13%
3,333
+952
+40% +$480K
CASC
86
DELISTED
Cascadian Therapeutics, Inc.
CASC
$1.51M 0.12%
154,167
+100,000
+185% +$981K
TCON
87
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$1.4M 0.11%
+500
New +$1.31M
AVGR
88
DELISTED
Avinger, Inc. Common Stock
AVGR
$1.25M 0.1%
+1
New +$1.38M
EYPT icon
89
EyePoint Inc
EYPT
$316M
$1.24M 0.1%
31,500
– –
UPI
90
DELISTED
UROPLASTY INC-NEW
UPI
$1.18M 0.09%
966,349
+200,000
+26% +$269K
ONCE
91
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.16M 0.09%
+15,000
New +$864K
ALIM
92
DELISTED
Alimera Sciences
ALIM
$1.16M 0.09%
15,460
-10,000
-39% -$787K
STML
93
DELISTED
Stemline Therapeutics, Inc.
STML
$1.15M 0.09%
+79,245
New +$1.21M
GRCE
94
Grace Therapeutics
GRCE
$46.9M
$1.13M 0.09%
4,928
-434
-8% -$102K
NGNE icon
95
Neurogene
NGNE
$674M
$1.11M 0.09%
6,500
– –
KERX
96
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.07M 0.08%
+84,380
New +$1.08M
GILD icon
97
Gilead Sciences
GILD
$181B
$981K 0.08%
+10,000
New +$1.02M
PARN
98
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
$964K 0.07%
196,500
-17,600
-8% -$81.4K
VNDA icon
99
CALL
Vanda Pharmaceuticals
VNDA
$302M
$930K 0.07%
100,000
-500,000
-83% -$5.65M
VNDA icon
100
PUT
Vanda Pharmaceuticals
VNDA
$302M
$930K 0.07%
100,000
– –
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2015 Portfolio in Review

As of Q1 2015, Perceptive Advisors held 207 positions worth $1.29B, up 7.9% from $1.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Perceptive Advisors withdrew a net $78.5M in Q1 2015, closing 51 positions and reducing 35 holdings. Its most notable exit was PTC Therapeutics, an estimated $34.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Perceptive Advisors opened a new position in Iovance Biotherapeutics worth $32.9M.

  • Perceptive Advisors's largest Q1 2015 buy was Iovance Biotherapeutics: 2,714,549 shares worth $32.9M.
  • Perceptive Advisors added most to uniQure in Q1 2015, an estimated $18.4M increase.
  • Perceptive Advisors's biggest Q1 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $21.8M.
  • Perceptive Advisors fully exited PTC Therapeutics in Q1 2015, selling an estimated $34.8M.
  • Perceptive Advisors's ten largest holdings make up 49% of its $1.29B portfolio in Q1 2015.
  • Perceptive Advisors opened 56 new positions and closed 51 in Q1 2015.
  • Perceptive Advisors's portfolio value rose 7.9% quarter-over-quarter to $1.29B.

Based on Perceptive Advisors's 13F filing for Q1 2015, filed 15 May 2015.